Valuation: PharmaEngine, Inc.

Market Cap 8.03B 248M 222M 205M 186M 348M 23.53B 352M 2.46B 977M 12.33B 930M 910M 39.1B P/E 2024
7.42x
P/E 2025 26.2x
Enterprise Value 3.36B 104M 92.91M 85.79M 77.8M 145M 9.83B 147M 1.03B 408M 5.15B 389M 380M 16.34B EV / Sales 2024
3.61x
EV / Sales 2025 5.97x
Free-Float
61.29%
Yield 2024
6.64%
Yield 2025 2.84%
1 day-0.53%
1 week-1.58%
Current month+0.54%
1 month+0.72%
3 months-15.17%
6 months+2.76%
Current year-20.60%
1 week 55.4
Extreme 55.4
57.3
1 month 55
Extreme 55
58
Current year 53
Extreme 53
74
1 year 53
Extreme 53
74.4
3 years 53
Extreme 53
123
5 years 53
Extreme 53
150.5
10 years 33.1
Extreme 33.1
197
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 17/05/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 19/01/2018
Director/Board Member - 13/06/2019
Director/Board Member - 15/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-1.58%-17.55%-48.00% 248M
-3.10%-3.43%+36.29%+67.69% 65.28B
+0.33%+0.33%+10.16%+78.07% 54.57B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.13%+2.09%+25.76%+51.97% 45.03B
-1.39%-5.08%+15.70%+114.12% 42.17B
+1.37%-5.20%+221.29%+901.16% 39.42B
-0.74%-4.84%+14.53%+44.45% 32.71B
-2.70%-7.34%+23.17%+0.36% 24.01B
+1.11%+15.18%+60.27%+49.33% 26.5B
Average -0.57%+1.62%+39.95%+136.12% 38.35B
Weighted average by Cap. -0.66%+1.72%+43.34%+155.35%

Financials

2024 2025
Net sales 2.52B 77.81M 69.84M 64.49M 58.48M 109M 7.39B 111M 773M 307M 3.87B 292M 286M 12.29B 911M 28.11M 25.23M 23.29M 21.12M 39.48M 2.67B 39.96M 279M 111M 1.4B 106M 103M 4.44B
Net income 1.75B 54M 48.46M 44.75M 40.58M 75.84M 5.13B 76.78M 537M 213M 2.69B 203M 198M 8.53B 388M 11.95M 10.73M 9.91M 8.98M 16.79M 1.14B 17M 119M 47.17M 595M 44.87M 43.91M 1.89B
Net Debt -3.85B -119M -107M -98.49M -89.31M -167M -11.29B -169M -1.18B -469M -5.92B -446M -437M -18.76B -4.67B -144M -129M -119M -108M -202M -13.69B -205M -1.43B -569M -7.18B -541M -530M -22.76B
Projected Income Statement - Annual - PharmaEngine, Inc.
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
27/10/26 NT$55.90 -0.53% 189,906
22/10/26 NT$56.20 0.00% 160,751
21/10/26 NT$56.20 -0.71% 176,738
20/10/26 NT$56.60 -0.35% 114,279
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - PharmaEngine, Inc.

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PharmaEngine, Inc.
  1. Stock Market
  2. Stocks
  3. 4162 Stock